Immupharma (IMM)

 

Latest News

Lupuzor trial on track, says ImmuPharma

ImmuPharma is on track to report top line results from its 52-week, randomised, double-blinded, phase III clinical trial of ...

Update on LupuzorT Pivotal Phase III Study

RNS Number: 3263V Immupharma PLC 02 November 2017 2 November 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") Update on Lupuzor Pivotal Phase III Study ImmuPharma PLC (LSE:IMM) , the specialist drug discovery and development company, is pleased to provide an update of its pivotal 52-week, randomised, double-blinded, Phase III clinic...

Holding(s) in Company

RNS Number: 7306T Immupharma PLC 16 October 2017 TR-1: S tandard form for notification of major holdings 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Immupharma Plc 213800VZKGHXC7VUS895 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK iss...

ImmuPharma completes sharing agreement with Lanstead

ImmuPharma has announced the completion of the sharing agreement entered into with Lanstead Capital in February 20...

All News

DateHeadlineSource
30-09-15Directorate ChangeRNS
30-09-15Interim ResultsRNS
29-07-15ImmuPharma chairman dies StockMarketWire
29-07-15Richard WarrRNS
27-07-15ImmuPharma clinical trials of Lupuzor 'live' StockMarketWire
27-07-15TERM SHEET SIGNED $14 MILLION FUNDING FOR LUPUZORRNS
25-06-15Lupuzor founder awarded 'CNRS Medal of Innovation'StockMarketWire
25-06-15Lupuzor's Founder Dr Slyviane Muller Awarded MedalRNS
29-05-15ImmuPharma resolutions passed at AGMStockMarketWire
29-05-15Result of AGMRNS
06-05-15Annual Report & AccountsRNS
06-05-15ImmuPharma appoints interim chairman StockMarketWire
06-05-15Interim Board ChangeRNS
30-04-15ImmuPharma losses narrow StockMarketWire
30-04-15Directorate ChangeRNS
30-04-15Preliminary ResultsRNS
11-02-15Immupharma completes clinical trial StockMarketWire
11-02-15CANCER UPDATE: IPP-204106RNS
27-01-15ImmuPharma gets assurance over EIS StockMarketWire
27-01-15Enterprise Investment Scheme StatusRNS
22-01-15FTSE surges as ECB unveils QE, financials riseStockMarketWire
22-01-15FTSE cautiously up as ECB's QE call nearsStockMarketWire
22-01-15Collaboration Agreement with Simbec-OrionRNS
30-10-14Holding(s) in CompanyRNS
28-10-14Holding(s) in CompanyRNS
21-10-14FTSE 100 makes strong recoveryStockMarketWire
21-10-14FTSE 100 bounces backStockMarketWire
21-10-14ImmuPharma raises £3.4m StockMarketWire
21-10-14Additional Listing - Conditional PlacingRNS
20-10-14ImmuPharma unit awarded €400,000 grant StockMarketWire
20-10-14ImmuPharma awarded EUR400,000 GrantRNS
30-09-14Losses remain at ImmuPharmaStockMarketWire
30-09-14Half Yearly ReportRNS
30-09-14LupuzorT Gears Up To Start Pivotal Phase III trialRNS
27-06-14Immupharma shareholders approve AGM resolutionsStockMarketWire
27-06-14Result of AGMRNS
27-06-14ImmuPharma extends research capabilitiesStockMarketWire
27-06-14Access to pioneering research in Bordeaux FranceRNS
16-06-14ImmuPharma granted new Nucant patents StockMarketWire
16-06-14NEW NUCANT PATENTSRNS

RSS feeds

  • Editorial news feed for LSE:IMM Editorial
  • Regulatory news feed for LSE:IMM Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account